Pliant Therapeutics (PLRX)
NASDAQ:PLRX
Total Valuation
Pliant Therapeutics has a market cap or net worth of $72.44M. The enterprise value is $56.10M.
Market Cap$72.44M
Enterprise Value$56.10M
Share Statistics
Pliant Therapeutics has 61,914,665 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61,914,665
Owned by Insiders2.48%
Owned by Institutions39.06%
Financial Efficiency
Pliant Therapeutics’s return on equity (ROE) is -0.82 and return on invested capital (ROIC) is -71.36%.
Return on Equity (ROE)-0.82
Return on Assets (ROA)-0.66
Return on Invested Capital (ROIC)-71.36%
Return on Capital Employed (ROCE)-0.72
Revenue Per Employee0.00
Profits Per Employee-873.36K
Employee Count171
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Pliant Therapeutics is ―. Pliant Therapeutics’s PEG ratio is 0.02.
PE Ratio―
PS Ratio0.00
PB Ratio0.41
Price to Fair Value0.41
Price to FCF-0.58
Price to Operating Cash Flow-0.56
PEG Ratio0.02
Income Statement
In the last 12 months, Pliant Therapeutics had revenue of 0.00 and earned -149.34M in profits. Earnings per share was -2.43.
Revenue0.00
Gross Profit-1.70M
Operating Income-150.07M
Pretax Income-149.34M
Net Income-149.34M
EBITDA-148.38M
Earnings Per Share (EPS)-2.43
Cash Flow
In the last 12 months, operating cash flow was -128.34M and capital expenditures -374.00K, giving a free cash flow of -128.71M billion.
Operating Cash Flow-128.34M
Free Cash Flow-128.71M
Free Cash Flow per Share-2.08
Dividends & Yields
Pliant Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.20
52-Week Price Change-20.41%
50-Day Moving Average1.26
200-Day Moving Average1.43
Relative Strength Index (RSI)39.00
Average Volume (3m)581.13K
Important Dates
Pliant Therapeutics upcoming earnings date is May 11, 2026, After Close (Confirmed).
Last Earnings DateMar 11, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
Pliant Therapeutics as a current ratio of 12.00, with Debt / Equity ratio of 16.06%
Current Ratio12.00
Quick Ratio12.00
Debt to Market Cap0.00
Net Debt to EBITDA0.11
Interest Coverage Ratio-58.65
Taxes
In the past 12 months, Pliant Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Pliant Therapeutics EV to EBITDA ratio is -0.39, with an EV/FCF ratio of -0.45.
EV to Sales0.00
EV to EBITDA-0.39
EV to Free Cash Flow-0.45
EV to Operating Cash Flow-0.46
Balance Sheet
Pliant Therapeutics has $190.94M in cash and marketable securities with $29.11M in debt, giving a net cash position of $161.84M billion.
Cash & Marketable Securities$190.94M
Total Debt$29.11M
Net Cash$161.84M
Net Cash Per Share$2.61
Tangible Book Value Per Share$2.95
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Pliant Therapeutics is $2.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.67
Price Target Upside128.21% Upside
Analyst ConsensusModerate Buy
Analyst Count5
Revenue Growth Forecast―
EPS Growth Forecast14.19%